Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -70.78
- Piotroski Score 2.00
- Grade Buy
- Symbol (GNPX)
- Company Genprex, Inc.
- Price $1.10
- Changes Percentage (-3.93%)
- Change -$0.05
- Day Low $1.08
- Day High $1.20
- Year High $14.40
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$18.81
- Trailing P/E Ratio -0.13
- Forward P/E Ratio -0.13
- P/E Growth -0.13
- Net Income $-30,860,461
Income Statement
Quarterly
Annual
Latest News of GNPX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance
Genprex, Inc. has finished the 0.09 mg/kg dose group of the Phase 1 Acclaim-3 clinical trial for Reqorsa® Gene Therapy in combination with Tecentriq® for small cell lung cancer patients....
By Yahoo! Finance | 1 month ago
